{
    "name": "ibritumomab tiuxetan",
    "comment": "Rx",
    "other_names": [
        "Zevalin"
    ],
    "classes": [
        "Antineoplastics",
        "Anti-CD20 Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/zevalin-ibritumomab-tiuxetan-342242",
    "pregnancy": {
        "common": [
            "Therapy may cause fetal harm when administered to a pregnant woman; immunoglobulins are known to cross the placenta; there are no available data on therapy use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage; advise women of childbearing potential to use adequate contraception for a minimum of twelve months; inform women who become pregnant while receiving therapy of the potential fetal risks"
        ],
        "specific": [
            {
                "type": "Reproductive potential",
                "description": [
                    "Therapy may cause fetal harm when administered to a pregnant woman"
                ]
            },
            {
                "type": "Pregnancy testing",
                "description": [
                    "Conduct pregnancy testing in females of reproductive potential prior to treatment"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females: Advise patients of reproductive potential to use effective contraceptive methods during treatment and for 12 months after last dose of therapeutic regimen",
                    "Males: Advise patients with female partners of reproductive  potential to use effective contraceptive methods during treatment and for 12 months after the final dose of therapeutic regimen"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on its radioactivity, there is potential risk that therapeutic regimen could cause toxic effects on male and female gonads"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug or metabolites in human milk, effects on breastfed child, or effects on milk production; because human IgG is excreted in human milk, it is expected that the drug would be present in human milk; due to potential for serious adverse reactions in a breastfeeding child, advise lactating women to avoid breastfeeding during treatment and for 6 months after last dose of therapeutic regimen"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "The drug should be administered under the supervision of a cancer chemotherapy physician qualified by training and experienced in the safe use and handling of radionuclides",
                "Fatal infusion reaction symptoms including hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock have occurred within 24 hr of rituximab infusion (~80% occurred in association with the first infusion); discontinue infusions and provide medical treatment to patients who experience infusion reactions",
                "Y-90 ibritumomab tiuxetan administration results in severe and prolonged cytopenias in most patients",
                "Do not administer to patients with greater than or equal to 25% lymphoma marrow involvement and/or impaired bone marrow reserve",
                "Do not exceed absolute maximum allowable dose of 32.0 mCi (1184 MBq) for Y-90 ibritumomab tiuxetan",
                "Do not administer Y-90 ibritumomab tiuxetan to patients with altered biodistribution as determined by imaging with In-111 ibritumomab tiuxetan",
                "Severe cutaneous and mucocutaneous reactions, some with fatal outcome, may occur in association with the ibritumomab tiuxetan therapeutic regimen",
                "Do not administer to patients experiencing a severe cutaneous or mucocutaneous reaction and provide prompt medical evaluation"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to any component (incl rituximab, yttrium chloride, indium chloride), murine proteins or to another monoclonal antibody",
                "Patients with >25% lymphoma marrow involvement and/or impaired bone marrow reserve",
                "Platelets <100 K/mm³, ANC <1500/mm³",
                "Do NOT administer Y-90 ibritumomab to patients with altered biodistribution as determined by In-111 ibritumomab imaging",
                "Hypocellular bone marrow, failed stem cell collection history, myeloablative therapy history",
                "Pregnancy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Patients with prior treatment with murine proteins should be screened for human anti-mouse antibodies",
                "Rituximab dose is lower when coadministered with ibritumomab than when use as a single agent",
                "Effective contraception should be used during and for up to 12 months after treatment",
                "Discontinue if patient develops infusion reaction symptom complex including hypoxia, pulmonary infiltrates, ARDS, MI, ventricular fibrillation, or cardiogenic shock",
                "Risk of severe and prolonged cytopenias; some complicated by hemorrhage and severe infection",
                "Risk of potentially fatal mucocutaneous reactions",
                "Live viral vaccine use, murine protein exposure history",
                "Drug not supplied radiolabeled, radiolabeling must be done in specialized facility",
                "Development of leukemia and myelodysplastic syndrome may occur; monitor patients for hematological toxicity including secondary malignancies",
                "Monitor for extravasation and terminate infusion if it occurs; resume infusion in another limb",
                "Do not administer live viral vaccines to patients who recently received therapy",
                "May cause fetal harm; advise patients of potential risk to a fetus and to use effective contraception"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Thrombocytopenia",
            "percent": "95"
        },
        {
            "name": "Neutropenia",
            "percent": "77"
        },
        {
            "name": "Anemia",
            "percent": "61"
        },
        {
            "name": "Asthenia",
            "percent": "43"
        },
        {
            "name": "Nausea",
            "percent": "31"
        },
        {
            "name": "Infections",
            "percent": "29"
        },
        {
            "name": "Chills",
            "percent": "24"
        },
        {
            "name": "Fever",
            "percent": "17"
        },
        {
            "name": "Abd pain",
            "percent": "16"
        },
        {
            "name": "Pain",
            "percent": "13"
        },
        {
            "name": "Vomiting",
            "percent": "12"
        },
        {
            "name": "HA",
            "percent": "12"
        },
        {
            "name": "Cough",
            "percent": "10"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        },
        {
            "name": "Diarrhea",
            "percent": "9"
        },
        {
            "name": "Pruritus",
            "percent": "9"
        },
        {
            "name": "Rash",
            "percent": "8"
        },
        {
            "name": "Anorexia",
            "percent": "8"
        },
        {
            "name": "Back pain",
            "percent": "8"
        },
        {
            "name": "Edema",
            "percent": "8"
        },
        {
            "name": "Arthralgia",
            "percent": "7"
        },
        {
            "name": "Myalgia",
            "percent": "7"
        },
        {
            "name": "Hypotension",
            "percent": "6"
        },
        {
            "name": "Flushing",
            "percent": "6"
        },
        {
            "name": "Constipation",
            "percent": "5"
        },
        {
            "name": "Urticaria",
            "percent": "4"
        },
        {
            "name": "Anxiety",
            "percent": "4"
        },
        {
            "name": "Dyspepsia",
            "percent": "4"
        },
        {
            "name": "Secondary malignancy",
            "percent": "2"
        }
    ]
}